A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting... by Fei, Yue, Li, Na, Qian, Weilin, Fan, Yang, Shen, Yu, Wang, Quanren, McLendon, Kristi, Shen, Kai

Get full text

S276: POVETACICEPT (ALPN‐303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY‐RELATED DISEASES by Dillon, Stacey, Davies, Rupert, Lickliter, Jason, Mclendon, Kristi, Manjarrez, Kristi Kristi L., Smith, Alina, Hudson, Krystalyn, Blanchfield, Lori, Sanderson, Russel, Chunyk, Allison, Blair, Tiffany, Enstrom, Amanda, Zayed, Hany, Peng, Stanford

Get full text

A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults by Davies, Rupert, Peng, Stanford L., Lickliter, Jason, McLendon, Kristi, Enstrom, Amanda, Chunyk, Allison G., Blanchfield, Lori, Wang, NingXin, Blair, Tiffany, Thomas, Heather M., Smith, Alina, Dillon, Stacey R.

Get full text

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial by Maurer, Marcus, Saini, Sarbjit S., McLendon, Kristi, Wabnitz, Paul, Kim, Sunghyun, Ahn, Keumyoung, Kim, Suyoung, Lee, Sewon, Grattan, Clive

Get full text

TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, v... by Demarchi, Martin, Coliat, Pierre, Mclendon, Kristi, Chung Shii Hii, Jocelyn, Feyaerts, Peggy, Ang, Felicia, Jaison, Litha, Deforce, Filip, Derde, Marie Paule, Kim, Michael Jinwoo, Park, Lisa Soyeon, Detappe, Alexandre, Pivot, Xavier

Get full text

Pharmacodynamics of CT-P39, a Proposed Biosimilar of Omalizumab, Comparing with EU-Xolair and US-Xolair; Result of a Phase 1, Randomized, Double-blind, Parallel Group, Single-dose... by Mclendon, Kristi, Wabnitz, Paul, Kim, Sung Hyun, Ahn, Keum Young, Kim, Su Young, Heo, Gyoung Jin, Ka, Ji Eun, In choi, Ji

Get full text

Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI-751): Results From a Randomized Phase 1 Trial by Hausfeld, Jeffrey N, Challand, Rodeina, McLendon, Kristi, Macapagal, Nathaniel, Bruce-Staskal, Pam, Fiaschetti, Christina, Sampey, Darryl B

Get full text

4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES by Dilllon, Stacey, Davies, Rupert, Lickliter, Jason, Mclendon, Kristi, Manjarrez, Kristi, Smith, Alina, Blanchfield, Lori, Sanderson, Russell, Chunyk, Allison, Enstrom, Amanda, Blair, Tiffany, Zayed, Hany, LI, Jiahua, Peng, Stanford

Get full text

A Hearing Intervention and Health-Related Quality of Life in Older Adults: A Secondary Analysis of the ACHIEVE Randomized Clinical Trial by Huang, Alison R, Morales, Emmanuel Garcia, Arnold, Michelle L, Burgard, Sheila, Couper, David, Deal, Jennifer A, Glynn, Nancy W, Gmelin, Theresa, Goman, Adele M, Gravens-Mueller, Lisa, Hayden, Kathleen M, Mitchell, Christine M, Pankow, James S, Pike, James R, Reed, Nicholas S, Sanchez, Victoria A, Schrack, Jennifer A, Sullivan, Kevin J, Coresh, Josef, Lin, Frank R, Chisolm, Theresa H

Get full text

Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR by Grunkemeier, M Natalie, Turner, Kristi, McLendon, Roger E

Get full text

Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR by Grunkemeier, M Natalie, Turner, Kristi, McLendon, Roger E

Get full text